Clinical and Commercial Pharmaceutical Market Research

Drug Development

• The State of Patient Recruitment in Clinical TrialsPharma decision-makers weigh in on topics effecting patient recruitment, including: drivers and barriers to success, valuable recruitment channels and methodologies, and the use of service providers.
• 2012 CRO Quality Benchmarking Report - Phase II/IIIBased on interviews with 125 pharmaceutical and biotechnology company representative - Respondents graded 25 small, mid-size and large CROs across 21 critically important capabilities that affect provider selection and delivery quality.
  
• The State of Clinical Study Feasibility This report examines how clinical study feasibility has changed, how it is likely to continue to change with the use of technology, and an analysis of service providers who provide feasibility services. 
  
• The State of Clinical Imaging An analysis of the clinical imaging services market, including service provider evaluations and anticipated market trends.
• The State of the Cardiac Safety/ECG Market in Clinical Trials An analysis of the ECG services market within clinical trials, ECG service providers' service quality, as well as attributes that sponsors seek when outsourcing ECG services.
• Post-marketing Safety Market Dynamics An analysis of the growth and decline of post-marketing safety activities including amount outsourced and sponsor's preferences for service providers.
• The State of the Phase I Market An analysis of market size, growth estimates, service quality, and loyalty profiles for Phase I service providers.
• 2011 CRO Quality Benchmark ReportInterviews with 150 pharmaceutical and biotech decision-makers resulted in this authoritative guide to buying and delivering quality product development services.
• The State of the EDC and ePRO MarketWith the industry's acceptance of EDC and ePRO technologies, ISR profiles users' awareness of technology providers and their satisfaction with well-known systems.
• CRO Selection for Small Pharma and BiotechProvides small pharma and biotech companies with the necessary tools to select the right CRO based upon their unique organizational needs.
• Clinical Development Staff Quality & Resourcing ModelsIn the product approval process, the quality of your development staff is as important as the efficacy of the compound.
• The Future of Clinical MonitoringThis report details the overall awareness, interest, and potential adoption of alternative models for clinical monitoring and how the clinical monitoring landscape will likely change over the next few years.
• The State of Adaptive TrialsPharmaceutical executives with adaptive trial conduct and outsourcing experience provide insight and advice for adaptive trial design and adoption.
• The Voice of the Site CoordinatorThis report analyzes recommendations from 120 site or study coordinators to enhance patient recruitment, develop closer relationships between CROs and sites, maintain site engagement, and improve feasibility estimates.
• The State of the Central Labs MarketInterviews with more than 100 central labs decision makers provide views about outsourcing, service provider selection strategies, and spending for central lab services.
• Late Phase Market DynamicsIn this study, 149 decision makers discuss in detail their plans for study conduct and outsourcing across various Late Phase study categories.
• Biopharma Outsourcing PerformanceThis report examines the outsourcing relationship from the CRO's perspective and benchmarks 53 sponsor companies' outsourcing operations and practices.
• 2010 Biotechnology Company Needs AssessmentThis report examines how outsourcing decisions are made for each phase of development: who the preferred service providers are, and how much outsourcing biotech companies plan to do by phase in the next year.
• The State of Biomarkers in Product DevelopmentParticipants provide insights into biomarkers strategies, experiences, and predictions for their adoption in drug development.
• 2010 Biosimilar Prescribing OutlookBased on interviews with 264 physicians in the United States and Western Europe, respondents provided their beliefs, attitudes, intentions, and expectations on a number of biosimilar related topics.
• 2010 CRO Quality BenchmarkingBased on interviews with 150 pharmaceutical and biotechnology company representative - Respondents graded 25 small, mid-size and large CROs across 20 important capabilities that affect provider selection and delivery quality.
• Patient and Investigator Recruitment SuccessMore than 350 patients, principal investigators and drug development professionals discuss in detail the drivers and barriers to successfully recruiting patients and investigators into clinical trials.
• 2009 CRO Quality Benchmarking ReportMore than 160 biotechnology company representatives graded 16 prominent service providers across 18 important capabilities that affect provider selection and delivery quality.